Stoyan A. Radkov, PhD

Stoyan A. Radkov, PhD

Technical Specialist

As an undergraduate, Dr Radkov studied Microbiology graduating in 1995 with the highest 1st Class BSc Honours degree in Microbiology at the Faculty of Animal & Microbial Sciences, University of Reading – awarded The Abbott Laboratories Prize for academic excellence. Dr Radkov attained a PhD in Viral Oncology from the Ludwig Institute for Cancer Research, St Mary’s Hospital – Imperial College London and was a Cancer Research Campaign (CRC) funded Senior Research Fellow at Imperial College London and University College London. His scientific findings were published in J. Virology and Nature Medicine.

After a successful career as a senior scientist at Imperial College London and University College London, researching in viral oncology, Dr Radkov trained as a biotech & pharmaceuticals patent attorney at top tier IP firm D Young & Co in England, before moving in-house to Pfizer, Sandwich, England and then Novartis and Syngenta, in Switzerland.

A few of Dr. Radkov’s publications are provided below.

2000 NATURE MEDICINE: The Latent Nuclear Antigen of Kaposi’s sarcoma associated herpes virus targets the retinoblastoma-E2F pathway and with the oncogene H-ras transforms primary rat cells.

1999 JOURNAL OF VIROLOGY: Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription

1997 JOURNAL OF VIROLOGY: Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.